SCWorx advances Nasdaq compliance plan as small-cap healthcare tech names navigate listing requirements

Exchange listing panels have worked through a sustained queue of minimum bid price cases among small-cap technology names, as prolonged equity market weakness pushed a broad segment of micro-cap shares below compliance thresholds. Against that backdrop, SCWorx Corp. (Nasdaq: WORX), a Middleton, Massachusetts provider of data normalization and supply chain solutions for the healthcare industry, said on July 29, 2026 that the Nasdaq Hearings Panel has issued a partial compliance letter confirming the company completed the first benchmark of its approved plan to maintain continued listing on The Nasdaq Capital Market.

One benchmark cleared, one condition remaining

The letter confirms progress, but stops short of full resolution. Under Nasdaq Listing Rule 5815(c)(4), SCWorx must still demonstrate compliance with the exchange's minimum bid price requirement. The specific test: a closing bid price of at least $1.00 per share for a minimum of twenty consecutive trading days.

The Panel's decision carries ongoing conditions as well. The company must immediately notify Nasdaq of any material changes to its compliance plan, or any event, condition, or circumstance that could affect its ability to satisfy the requirements of the previously granted exception. The Panel retained the right to reconsider the terms of that exception if any development arises that, in its judgment, makes continued listing inadvisable or unwarranted.

The sector-wide read-through

For small-cap healthcare data and supply chain software names, compliance sequences like this have become part of the operating calendar. Minimum bid price notices typically follow extended equity price weakness, which in this segment reflects a demand environment where smaller technology vendors compete for hospital system budgets that have tightened. That pressure flows into share prices and, eventually, into hearing rooms.

SCWorx's platform focuses on data management and analytics for healthcare organizations, with products built around the normalization and aggregation of complex data sets to support supply chain optimization and financial performance. The read-through for sector peers is directional: exchange panels are processing these cases on a structured timeline, and a partial compliance acknowledgment signals that at least one plan in the broader cycle is advancing as filed.

Management's position

Tim Hannibal, President and Chief Executive Officer of SCWorx, said maintaining the Nasdaq listing is a strategic priority as the company continues expanding customer relationships and advancing its healthcare supply chain data management platform, with the stated aim of creating long-term value for shareholders. SCWorx said it intends to take all actions necessary to satisfy the Panel's conditions and will continue updating investors on its progress.

The compliance clock is still running. Reaching twenty consecutive closing days above $1.00 per share, the remaining threshold under Listing Rule 5815(c)(4), is what will determine whether the listing survives on the Panel's current terms.

Related reading

• Humana holds 2026 profit floor as medical cost trends track to plan
• Intuitive Surgical selloff after earnings reopens valuation debate in surgical robotics